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111 Characterization of bacterial strains isolated from the CF patients
in Georgia and evaluation of the efﬁcacy of phage treatment
M.I. Kutateladze1, E.S. Tevdoradze1, N.S. Balarjishvili1, N.R. Skhirtladze1,
R.S. Adamia1, T.I. Tophuria2. 1Eliava Institute of Bacteriophages, Microbiology
and Virology, Tbilisi, Georgia; 2Cystic Fibrosis National Center, Tbilisi, Georgia
We reviewed the patients attending the “Cystic Fibrosis National Center” in Tbilisi,
Georgia from November, 2006 until October, 2008. All strains isolated from the
patients’ specimens were subjected to taxonomic analysis. For the genus- and
species-level identiﬁcation of the bacterial strains PCR analysis was used. Genetic
relatedness of bacterial strains was determined by PFGE. Antibiotic susceptibility of
the strains was determined by the disc diffusion method. 30 strains of P. aeruginosa
and 76 strains of S. aureus have been identiﬁed. Phage sensitivity in vitro was de-
termined using Pyophage. Four patients who were diagnosed to have cystic ﬁbrosis
were selected for Pyophage application (by nebulizer administration). According to
the bacteriological testing, in two out of four patients S. aureus and P. aeruginosa
were the main causative agents of the secondary infections. The other two were
infected only by S. aureus. All patients were treated by the standard scheme of
therapy, including antibiotics, anti-mucus medications and vitamins. We studied
the bacterial cultures before, after and during the treatment, including checking
antibiotic- and phage-resistance and PFGE. The existence of phage-neutralizing
antibodies was checked in all patients’ blood sera. The treatment continued for
6−10 days (several times); titter of bacterial cells isolated has been drastically
decreased and the general state of the patients was clearly improved: expectoration
was facilitated, and no crepitating was observed. Bacteriophage treatment provided
long infection-free periods between colonization episodes
Supported by: PhageBiotics Foundation.
112 A gift of Nature for the treatment of Pseudomonas aeruginosa,
Burkholderia cepacia and MRSA in Cystic Fibrosis cases
C. Sandre-Ballester1. 1ALAXIA, Vaulx-En-Velin, France
The CFTR gene is responsible for the production of a protein regulating outﬂow of
water and salts (like Cl− or SCN−) from epithelial cells. Inactivation of CFTR is
likely to cause multiple defects in the airway that together alter local innate immunity.
As shown in recent publications, hypothiocyanite (OSCN−) antimicrobial molecule is
deﬁcient in CF condition.
OSCN− is well known by ALAXIA scientists who demonstrated with appointed experts
during MEVEOL development its antimicrobial efﬁcacy on various strains including
MRSA, B. cepacia, and mucoid P. aeruginosa.
MEVEOL tackles a wide range of microorganisms including bioﬁlm due to its
composition associating naturally linked compounds. OSCN− and lactoferrin, main
biomolecules, are normally present in human body and especially in human airways
suggesting low risk of bacterial resistance.
Effects of MEVEOL have been evaluated in vitro and in vivo.
MEVEOL (inhalation use) will be of potential signiﬁcant beneﬁt for the treatment of
lung microorganisms proliferation in CF condition thanks to its combined antimicrobial
and local mechanism of action.
Supported by: Project initiated and supported by Cystic Fibrosis non proﬁt organisation
Mucoviscidose Innovation & with the collaboration of Vaincre la Mucoviscidose
In vitro efﬁcacy vs B. cepacia (log CFU/mL)
Contact time (h)
0 1 2 4 6 24
Control 4.41 4.48 4.54 4.56 4.58 4.53
MEVEOL 4.41 3.49 2.99 2 1.84 1.56
MEVEOL + peroxidase system 4.41 0.3 0 0 0 0
Same kind of results on MRSA, Pseudomonas.
In vivo demonstration of efﬁcacy on mice, previously infected with mucoid P. aeruginosa (log
CFU/mL)
Control Treated with Meveol
Mice lung 72 h after infection 3.1 1.5
Same kind of results on MRSA, Pseudomonas.
113 Orphan drug designation to Anti-pseudomonas IgY
E. Nilsson1, A.E. Hollsing2, A. Larsson1, H. Kollberg2. 1Dept. Medical Sciences,
Clinical Chemistry, Uppsala University, Uppsala, Sweden; 2CF Centre, University
Children’s Hospital, Uppsala University, Uppsala, Sweden
Pseudomonas aeruginosa (PA) lung infections are main causes of morbidity and
mortality in CF. Repeated courses of antibiotics give fewer infections and improved
prognosis, but the threat of serious side effects by the use of antibiotics is a
reality – especially the rapidly increasing antibiotic resistance. Alternatives and/or
complements to antibiotics are urgently needed.
Passive immunization is a known alternative to ﬁght infections. Hens produce
large amounts of antibodies, IgY, which can be retrieved from egg yolk. Hens
are vaccinated with PA in order to obtain speciﬁc Anti-pseudomonas IgY (Anti-PA
IgY), which are used for oral treatment to prevent PA lung infections. Humans do
not produce anti-IgY antibodies to orally given IgY and the toxicity is very low.
Moreover, the risk that bacteria should develop resistance to IgY is extremely small.
Anti-PA IgY treatment to CF patients in a clinical trial reduced the number of PA
positive cultures and tended to delay the onset of chronic PA infections. Thus, the
need for antibiotics was reduced. Atypical mycobacteria and A. xylosoxidans only
appeared sporadically and there have been no cultures positive for B. cepacia. BMI
was normal or close to normal and pulmonary function was preserved within the
group at the end of the study (Ped Pulm, 2008).
Due to these results Anti-PA IgY has been granted orphan drug designation by
EMEA for the orphan indication: treatment of cystic ﬁbrosis. EMEAs motivation
was: “. . . justiﬁcations have been provided that avian polyclonal IgY antibody
against Pseudomonas aeruginosa may be of signiﬁcant beneﬁt to those affected
by the condition.”
We are now searching ﬁnancial support for a Phase III study.
114* Activity of liposomal formulations on sputum isolated from
CF Patients
M. Halwani1, S. Hebert1, Z.E. Suntres1, M. Alipour1, A. Omri1. 1Laurentian
University, Sudbury, ON, Canada
Opportunistic pathogens like the Gram-negative Pseudomonas aeruginosa develop
resistance by forming bioﬁlm, controlled by Quorum Sensing (QS) molecules.
We have developed a novel liposomal formulation by co-encapsulating the bis-
muth metal (Bi) with tobramycin (Tob). It is hypothesized that delivery of bi-
functional liposomes containing both Bi and Tob would increase their antibacterial
efﬁcacy. The stability of the liposomal-bismuth-tobramycin formulation (LipoBT)
was measured in bronchoalveolar lavage (BAL) and sputum, and their activities
against clinical isolates of P. aeruginosa grown on bioﬁlms were compared to the
conventional forms by using the Calgary Bioﬁlm Device. QS reduction on isolates
of P. aeruginosa was determined by monitoring the N-acyl homoserine lactone
(AHL) production after exposure to LipoBT formulation using an Agrobacterium
tumefaciens reporter strain. Sputum penetration by LipoBT was determined by
comparing its penetration with latex bead particles equaling liposome particle size.
The LipoBT formulations tended to be stable in sputum and BAL. Encapsulated
Tob in LipoBT formulation eradicated bacterial growth in bioﬁlms at concentrations
of 64 to 512mg/L, whereas, other Tob formulations were only able to reduce
the growth log compared to positive control. Our LipoBT formulation was able
to prevent QS signaling production at concentrations as low as 0.012mg/L of
Tob in absence of the bactericidal activity. LipoBT formulation was also able to
penetrate diluted sputum samples more efﬁciently than latex beads. In conclusion,
co-encapsulating Bi with Tob establishes a new strategy for higher efﬁcacy of these
agents by promoting their antimicrobial activity and eradicating bioﬁlms produced
by mucoid bacterial strains.
